#### Original article

- 2 Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19
- 3 among first, second, and third waves in Dhaka Medical College
- 4 Authors:

- 5 1. **Dr. Reaz Mahmud FCPS, MD**, Assistant Professor, Department of Neurology, Dhaka
- 6 Medical College. Dhaka, Bangladesh. Phone-+8801912270803. <u>E-mail-</u>
- 7 <u>reazdmc22@yahoo.com</u> and <u>rmahmudneuro@dmc.gov.bd</u>. ORCID ID-0000-0002-9427-
- 8 1746.
- 9 2. Dr. Md. Ashikul Islam, MD, Indoor Medical Officer, National Institute of
- neurosciences and Hospital. Dhaka, Bangladesh. phone: 01737104013, mail-
- 11 <u>ashikdmc62@gmail.com</u>, ORCID ID -0000-0001-8331-1362
- 3. Dr. Md. Emdadul Haque, MD, Medical officer, Department of Neurology, Dhaka
- Medical College. Dhaka, Bangladesh. phone: 0714560256, mail-
- dr.emdadmithu@gmail.com, ORCID ID 0000-0001-6870-6075
- 4. Dr. Md. Dewan Azmal Hussain, Assistant professor, National Institute of Chest
- diseases and Hospital, Phone: +8801819449812, Mail: azmal.dr@gmail.com
- 5. **Dr. Mohammad Rafigul Islam**, Associate professor, Department of Medicine, shaheed
- Suhrawardy Medical college. Phone-+8801624413595, Mail: drrafiq73@yahoo.com.
- 6. **Dr. Farhana Binte Monayem, MBBS**, Medical officer, Sarkari karmachari Hospital.
- Dhaka, Bangladesh. Phone-+8801920155971. Mail-farhanabintemonayem@gmail.com.
- 21 ORCID ID-0000-0001-5023-0638.
- 7. **Dr. Mostofa Kamal, MD,** Assistant professor, Department of Medicine, Dhaka Medical
- College. Phone-+8801711582960, mail- mkamal052@gmail.com

- 8. **Dr. Hashmi Sina MRCP, MD,** Assistant professor, Department of Neurology, Dhaka
- 25 Medical College. Dhaka, Bangladesh. Phone-+88017189675269, E-mail:
- 26 hashmi.sina49@gmail.com
- 9. **Dr. Mohammad Fakhrul Islam, MD,** Assistant professor, Department of Neurology,
- Dhaka Medical College. Dhaka, Bangladesh. Phone-+88001937859810, mail-
- fakhrulislam.work@gmail.com.
- 30 10. Dr. Ponkaj Kanti Datta, Assistant professor, Department of Medicine, Dhaka Medical
- College, Dhaka, Bangladesh. Phone number: +8801711069701. Mail-
- 32 ponkajdatta@yahoo.com. ORCID ID: 0000-0002-4508-4549
- 11. Dr. S.K. Jakaria Been Sayeed, MRCP, Indoor Medical Officer, National Institute of
- neurosciences and Hospital. Dhaka, Bangladesh Phone- +8801783335147. Mail-
- 35 <u>skjakaria1@gmail.com</u>. ORCID ID-0000-0003-1173-4248.
- 12. Dr. Sabbir Ahmed Dhali, MD, Registrar, Department of Neurology, Dhaka Medical
- 37 College. Dhaka, Bangladesh. Phone-+8801720015583. Mail-dr.sabbirdhali@gmail.com.
- 13. **Dr. Khairul Islam, FCPS**. Junior consultant, Department of Medicine, Dhaka Medical
- College, Dhaka, Bangladesh. phone-+8801717696207. Mail-
- 40 khairul0696207@gmail.com, ORCHID: 00 00000188716270.
- 41 14. **Dr. Rifat Hossain Ratul**, Medical Officer, COVID-19 post-acute care and follow-up
- 42 clinic, Dhaka Medical College. Phone:01631907154, Mail: dr.ratulrifat@gmail.com.
- 43 15. Dr. SK Md. Rubaed Hossain, Research Assistant, Stroke registry, Department of
- Neurology, Dhaka Medical College. Dhaka, Bangladesh, Phone: 01680888637, Mail:
- 45 dr.rubaed94@gmail.com.

16. Habib Naziat Prince, MSC, Research Assistant, North South University, phone:

- 47 +8801647237397. Mail- habib.52statru@gmail.com
- 48 17. **Dr. Ahmed Hossain Chowdhury**, MD, Associate Professor, Department of Neurology,
- Dhaka Medical College. Dhaka, Bangladesh. Cell no: +88001712257206. Mail:
- ahmedssmc17@yahoo.com.
- 51 18. **Dr. Kazi Gias Uddin Ahmed**, Associate Professor and Head, Department of Neurology,
- Dhaka Medical College. Dhaka, Bangladesh. Phone-01611272277 mail-
- 53 kazi17k43@gmail.com. ORCID ID-0000-0002-0163-8271
- 54 19. Dr. Md.Titu Miah, Principal and Professor of Medicine, Department of Medicine,
- Dhaka Medical College, Dhaka, Bangladesh. **Mobile:** +8801711591770. Mail:
- 56 <u>titum21@gmail.com</u>
- 57 20. Dr. Md. Mujibur Rahman FCPS, MD, FACP Professor, Department of Medicine,
- Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh Phone-
- 59 01711525406 Mail-mmrahman61@gmail.com. ORCID Identifier: 0000-0002-4381-
- 60 1511.
- 61 **Data availability statement:** The data will be within the paper and uploaded as supplementary
- 62 file.
- A funding statement: This research received grant from Director General of Health Services,
- 64 Government of the peoples' republic of Bangladesh.
- 65 **Conflict of interest disclosure:** The authors declare that there is no conflict of interest.
- **Ethics approval statement:** The Institutional Ethical Committee of Dhaka Medical College
- approved the study (ERC-DMC/ECC/2021/55).

**Patient consent statement:** As we mainly reviewed hospital data, there was no scope for written consent. We took verbal permission from the patient for post-covid follow-up. Permission to reproduce material from other sources: Not applicable Clinical trial registration: Not applicable **Corresponding Author:** Dr. Reaz Mahmud, Assistant Professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Phone-+8801912270803. E-mail-reazdmc22@yahoo.com. rmahmudneuro@dmc.gov.bd. ORCID ID-0000-0002-9427-1746 

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19 among first, second, and third waves in Dhaka Medical College Abstract: **Background** This study aimed to examine the differences in epidemiologic and disease aspects among patients with COVID-19 **Methods:** We reviewed the hospital records between April 2020 and September 2021 and followed up on the patients for post-COVID complications. **Findings:** Older adult patients were predominantly affected during the first and second waves, followed by middle-aged patients. Men were predominantly admitted, considering the three waves; although more women were admitted in the second wave. Cough was more common in the second and third waves than in the first wave 522 (59.7%). Respiratory distress was the most common in the third wave, 251(67.1%), and least common in the first wave 403 (46.1%). Anosmia was more common in the third wave 116 (31.2%). In the third wave, patients presenting in a critical state 23 (6.2%) and severe disease 152 (40.8%) were more common. The hospital admission median (IQR) was longer in the first wave, 12 (8–20), than in other waves. More patients were admitted in the first wave (52%) than in the other waves, and patients received more oxygen in the third wave (75%) than in the other waves. Death occurred more commonly in the first wave (51%) than in the other waves. Patients were investigated more commonly in the first and third waves

than in the second wave. The positivity rate was high in the third wave (22.8%) than in other waves. In the third wave, the positivity rate was higher in women (24.3%) than in men. Post-covid cough increased in the second wave and fatigue was higher in the third wave than in other waves. Tiredness and memory loss was greater during the second wave than in other waves.

#### **Conclusion:**

This study revealed that the presenting symptoms, outcomes, and epidemiologic trends differed

during the COVID-19 waves.

#### Introduction

On December 31 World Health Organization (WHO) formally reported a case of atypical pneumonia in Wuhan City, China [1], which was later named coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. On March 11, 2020, WHO declared the novel coronavirus (COVID-19) outbreak a global pandemic [3].

The WHO classified the phases of the pandemic as phases 1–3(predominantly animal infection, few human infections), phase 4(sustained human-to-human infection), phases 5 and 6 (widespread human infection), post-peak (possibility of recurrent events), and post-pandemic (disease activity at seasonal level) [4]. Most of the worst pandemics lasted for several years [5]. After studying the transmission dynamics of SARS-CoV-2, researchers postulated that it would reach long-term circulation within the next five years [6]. Experience in the last 2 years has revealed that resurgence as "waves" is common [4], and the overall pattern of the coronavirus pandemic has been a series of increased COVID-19 waves: which gradually declines. Several outbreaks of illnesses have occurred in various parts of the world. Europe entered its third phase in March 2021 [7], and the United States is likely to experience the 4th wave [8]. The reason for

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

the seasonal variation in transmission, duration of immunity, degree of cross-immunity between SARS-CoV-2 and other coronaviruses, intensity and timing of control measures [7], and not the least viral mutation can all explain the wave and gradual decline of cases (waves of the disease). [10]. SARS-CoV-2 has mutated at a pace of about 1–2 mutations per month throughout the current global crisis [11]. A variant of SARS-CoV-2 with the D614G mutation emerged in China in late January and early February 2020 and immediately became the dominant form of the virus circulating globally [10]. Subsequently, several mutations were recognized as mutations of concern, naming the UK variant known as 501Y. V1, VOC 202012/01, and B.1.1.7, a South African variant known as the 501Y. V2, or B.1.351, a Brazilian variant known as 501Y. V3 or P.1 lineage [11, 12, 13], and the Indian variant B.1.617 (double mutant) [14]. The Indian variant gave rise to India's second wave and stressed its health system. In terms of test positivity rates (TPRs) and case fatality rates (CFRs), the epidemiologic characteristics seem to differ from those of the first wave [15]. Bangladesh reported the peak of the second wave in late February 2021 and the third wave in June 2021 [16]. In the second wave, death rate increased among the young [17]. The African variant was responsible for more than 80% of the second wave, while the delta variant was responsible for 78% of the third wave [17,18]. Preliminary reports of various SARS-CoV-2 mutant strains show transmissibility, severity, and case mortality diversity. The initial study about the African variant reported no significant correlation between severe disease and outcomes. However, higher transmissibility is possible. The mutant virus behavior in Bangladeshi populations remains largely unknown. Therefore, this study aimed to systematically and scientifically observe the difference in the presentation and outcome of patients with COVID-19 between the first, second, and third waves.

Additionally, we examined the positivity rate, hospital admission rate, and death rate in outpatient department patients.

#### **Materials and Methods**

158

159

160

161

162

163

164

165

166

167

168

169

170

171

173

This study aimed to examine differences in the epidemiology of COVID-19 in the first, second, and third waves. We aimed to find if there were any variations in the symptoms, disease severity, case fatality, length of hospital stay, frequency of patients requiring oxygen therapy, and referrals to the intensive care unit (ICU). We reviewed the outpatient data for clinic attendance, hospital admission rate, and death in the outpatient department. We examined the virology laboratory data to observe differences in the positivity rate, number of tests, and age and sex. We reviewed inpatient hospital data for rates of hospital admission and death. We found differences in complications of COVID-19 in patients followed up for at least 6 months after hospital discharge during the first, second, and third waves of COVID-19.

#### Study area and period

- The study was conducted at Dhaka Medical College Hospital between January 01, 2021, and
- 172 June 20, 2022.

#### Study design

- We conducted a cross-sectional study and a review of the hospital records. We reviewed the
- hospital records of outpatients, inpatients, and virology departments. We examined the patients'
- medical. Some patients were followed up for at least 6 months after discharge for post-COVID-
- 177 19 complications. The telephone interviews followed pre-specified telephone interview
- 178 guidelines.

#### Source population

180 The Dhaka Medical College Hospital inpatient were the source population.

#### **Study population**

- The study population included inpatients and patients who called back at least 6 months after
- 183 follow-up.

179

181

184

190

199

#### Eligibility criteria

- The study included patients' records, containing important demographics such as age, sex, area
- of residence, telephone number, complete treatment sheet, admission and discharge date, and at
- least a brief history. Patients more than 18 years of age, with RT-PCR positive test results
- irrespective of the severity of the disease admitted between April 2020 and September 2022 were
- included in this study for analysis and follow-up.

#### Sample size determination

- 191 The sample size was calculated using the formula below, and the hypothesis was that there was
- no variation in presentation between the COVID-19 waves in Bangladesh during the pandemic:

193 
$$n = \frac{\left[Z\alpha\sqrt{2p(1-p)} + Z_{\beta}\sqrt{p_1(1-p_1) + p_2(1-p_2)}\right]^2}{(p_1 - p_2)^2}$$

- 194 Here, Zα=1.96 Z value of standard normal distribution at 95% confidence interval,
- 195 P1=prevalence of severe infection in the first wave, P2=Prevalence of severe disease in the
- second wave, RR=1.5[risk ratio], P2=0.12; in one study in Bangladesh, the prevalence of severe
- infection was 11.5% [19], P1=RR×p2=0.18, Z $\beta$ =0.84 at 80% power, P= (p1+p2) ÷2=0.15. Thus,
- the estimated sample size was 240 for each wave.

#### Sampling technique and procedure

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Cluster sampling methods were used. We compiled a list of all wards where patients with COVID-19 had been admitted. We selected one male ward and one female ward. We subsequently reviewed all records that met the inclusion and exclusion criteria. We selected post-COVID follow-up with non-random sampling methods. **Study variables** The variables included in the study were **Demographic variable:** Age of the respondents in years and sex Presenting features of COVID-19: Fever, cough, respiratory distress, sore throat, nausea, vomiting, diarrhea, and body ache. Investigations in COVID-19 state: Total blood count, CRP, D-dimer, creatinine, and ferritin levels. **COVID-19-severity:** COVID-19 positivity, symptoms in case of COVID-19 positivity (asymptomatic, mild, moderate, severe, or critical) **Duration:** Duration between symptom onset and hospital admission, length of hospital stay. Post-COVID-19 conditions: Fatigue, cough, respiratory distress, insomnia, etc. Outcome-related questions: Discharged and death. Oxygen requirement, ICU referral Functional impact: We examined functional implications in the post-covid state for at least 6 months for overall functional status, fatigue score, and depression score. **Operational definition:** Confirmed Covid-19, and its different severities were defined according to the WHO and National guidelines [19, 20]. Case fatality rate:

NUMBER OF TOTAL DEATH SURING THE SAME PERIOD IN THE SAME WARD CFR= NUMBER OF TOTAL ADMISSION IN THE DEFINED PERIOD IN THE SELECTED WARD 221 X100 222 223 224 **Duration of hospital stay**: The total period from the day of admission to the day of discharge. Waves of infection: The first, second, and third waves extend between April 2020 to January 225 2020, February 2021 and May 2021, and June 2021 and September 2021, respectively [21,22]. 226 227 Post-COVID-19 condition: According to the Center for Disease Control, USA [23] Post-COVID conditions include a wide range of new, returning, or ongoing health problems that 228 people experience after contracting the SARS-CoV-2 causing COVID-19. 229 **Post-COVID fatigue**: The diagnostic criteria for post-COVID-19 fatigue were developed 230 231 according to the United States Institute of Medicine symptom criteria [24]. The Chalder Fatigue Scale [25], the Karnofsky Performance Status Scale [26], and the 232 233 depression scale were used to assess fatigue severity, overall functional status, and depression 234 [27]. **Data collection instrument** 235 For patients admitted to the hospital, data were collected on a data collection sheet. A telephone 236 directory was used for Post COVID-19 follow-up. We collected data from reports of outpatient, 237 inpatient, and virology departments. 238 **Data Collection procedure** 239 We collected all patients' files from the hospital record unit in the selected ward. Each file was 240 evaluated by one data collector and researcher. The completed data collecting sheet contains a 241 list of all available information. We obtained no specific procedure for missing data and 242 excluded files that did not contain essential information, such as patient demographics, 243

admission date, and discharge date. We collected the phone number from the hospital records and interviewed the patients for post-covid -19 complications at least 6 months after recovery. We collected data from the outpatient, inpatient, and virology departments using the Excel datasheet, which contains the patient's name, age, sex, date of attendance, outcome, admission, death, discharge, positive or negative status, etc. **Data Quality Control** 

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

Each data sheet was reviewed by two researchers; disagreements were resolved through discussion. We removed responses where respondents provided contradictory answers. Because each patient was coded and had a specified hospital record number, there was no scope for double responses.

#### **Data Processing and Analysis**

R (v4.1.1) was used to process data. We performed a network analysis with a tidy verse and q graph. Qualitative data with normal distribution were expressed as means (SD), while nonnormal data were expressed as medians (IQR). We divided the respondents into groups of first, second, and third waves. We used the chi-square test to calculate quantitative data and one-way ANOVA to calculate quantitative data. A needed we used a post hoc analysis with Bonferroni adjustment, Dunn test, and Tukey's test. We determined epidemiological trends in the EXECL sheet. The p-value for statistical significance was set at <0.05. We did not impute any missing values, and they were included in the analysis.

#### **Ethical consideration**

The Institutional Ethical Committee of Dhaka Medical College approved this study (ERC-DMC/ECC/2021/55). As we mainly reviewed the hospital data, there was no need for written consent. The patients provided verbal consent for post-covid follow-up.

#### **Results**

We reviewed 1766 patient records and included 1597 patients' data for analysis in this mixed study of retrospective hospital review of hospital data and cross-sectional follow-up of patients admitted for post-COVID-19 complications. From these patients we followed 600 patients over the telephone for post-COVID-19 complications. Between April 2020 and September 2021, and 38578 patients visited the outpatient department, 24501 patients were admitted, 57857 were tested for treatment at the virology department (Suppliment1).

Table 1: Demographic characteristics and co-morbidity of the admitted patients in the three waves

Variable	Categories	Total patient	First wave a	Second	Third wave c	P
		(n=1595)	(n=874)	wave <sup>b</sup>	(n=372)	value
		(N)	(N) %	(n=349)	(N) %	
				(N) %		
Age		47.91(15.67)	43.82(14.31)	50.79(15.95)	54.62(15.61)	<0.001
(n=1597),						
mean (SD)						
	<40 years	512	364	84	64	
		32.1%	41.6%	24.1%	17.2%	

Age						<0.001
(n= 1595)	40-60	652	366	139	147	
	years	40.8%	41.9%	39.8%	39.5%	
	60+ years	431	144	126	161	
		27.02%	54.8%	36.1%	43.3%	
	Female	627	283	191	153	
sex		39.31%	32.4%	54.7%	41.0%	< 0.001
(n= 1595)	Male	968	590	158	220	
		60.68%	67.6%	45.3%	59.0%	
Fever	Present	1366	738	296	332	
(n= 1595)		85.6%	84.4%	85.1%	89.0%	0.1
Cough	Present	1040	522	228	290	
(n= 1595)		65.2%	59.7%	65.5%	78.0%	<0.001
Running	Present	206	143	16	47	
nose		12.9%	16.4%	4.6%	12.6%	< 0.001
(n= 1595)						
Respiratory	Present	848	403	194	251	
distress		(53.1)	46.1%	55.7%	67.1%	< 0.001
(n= 1595)						
Sore throat	Present	278	198	33	47	
(n= 1595)		17.4%	22.7%	9.5%	12.6%	<0.001

Hoarseness	Present	24	11	5	8	
of voice		1.5%	1.3%	1.4%	2.1%	0.50
(n= 1595)						
Chest pain	Present	107	52	19	36	
(n= 1595)		6.7%	6.0%	5.4%	9.6%	0.03
Diarrhea	Present	152	74	18	60	
(n= 1595)		9.5%	8.5%	5.2%	16.1%	<0.001
Vomiting	Present	96	29	8	59	
(n= 1595)		6.1%	3.3%	2.3%	15.9%	< 0.001
Anorexia	Present	274	123	38	113	
(n= 1594)		17.1%	14.1%	11.0%	30.2%	<0.001
Anosmia	Present	301	158	27	116	
(n= 1593)		18.8%	18.1%	7.8%	31.2%	<0.001
Headache	Present	252	145	25	82	
(n= 1583)		15.7%	16.6%	7.2%	22.5%	<0.001
Lethargy	Present	436	231	106	99	
(n= 1597)			26.4%	30.4%	26.5%	0.35
Body ache	Present	286	107	87	92	
(n= 1596)			12.2%	25.0%	24.6%	<0.001
	Critical <sup>f</sup>	25	0	2	23	
		1.5%	0.0%	0.6%	6.2%	
	Mild <sup>g</sup>	747	422	216	109	
Presenting		29.7%	48.3%	61.9%	29.2%	<0.001

severity d						
(n= 1595)	Moderate <sup>h</sup>	648	443	116	89	
		40.6%	50.7%	33.2%	23.9%	
	Severei	175	8	15	152	
		10.9%	0.9%	4.3%	40.8%	
	Critical <sup>f</sup>	107	32	3	72	
			3.7%	0.9%	19.3%	
Ultimate	Mild <sup>g</sup>	627	365	183	79	
severity <sup>e</sup>			41.8%	52.9%	21.1%	< 0.001
(n= 1595)	Moderate <sup>h</sup>	589	383	128	78	
			43.8%	37.0%	20.9%	
	Severei	271	94	32	145	
			10.8%	9.2%	38.8%	
Diabetes	Present	531	216	136	179	
(n= 1151)		33.2%	28.4%	38.8%	48.1%	<0.001
Hypertension	Present	532	182	142	208	
(n= 1154)		33.3	24.5%	40.6%	55.9%	<0.001
Asthma	Present	114	57	30	27	
(n= 931)		7.1%	8.0%	8.5%	16.0%	<0.001
IHD	Present	123	29	31	63	
(n= 930)		7.7	4.1%	8.8%	16.9%	<0.001
Renal	Present	103	24	32	47	
disease		6.4%	3.4%	9.1%	12.6%	<0.001

(n= 926)

- a- From April 2020 to January 2020,
- b- From February 2021 to May 2021

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

- c- From June 2021 to September 2021
- d- The severity of the patient at the time of hospital admission
- e- The severity of the patient in the course of the hospital stays
- f- Critical: Patient requiring high flow oxygen or mechanical ventilation
- g- Mild: Patients having mild symptoms of upper respiratory tract viral infection, including mild fever, cough (dry), sore throat, nasal congestion, malaise, headache, muscle pain, anosmia, or malaise;
- h- Moderate: the patient has respiratory symptoms such as cough and shortness of breath are present without signs of severe pneumonia (tachypnea >30 breaths/min and hypoxia: oxygen saturation <90% on room air).
- i- Severe: Patients with severe pneumonia require supplemental oxygen through nasal canal, facemask, or face mask with reservoir.

The mean age (SD) of the hospital-admitted patients was 47.91(15.67) years, with patients in the and third waves being higher than those in the first wave (p <0.001). Patients above 60 years were mainly involved in the first wave 144 (54.8%), the 40–60 age group was primarily involved in the second wave 139 (39.8%), and those above 60 years were more likely to be infected in the third wave 161 (43.3%).

Men were predominantly admitted 968 (60.68%). However, in the second wave, the number of women, 191 (54.7%), was higher.

Fever was present in 1366 (85.6%) patients and did not differ among the three waves (p = 0.1). Cough was more prevalent in the second 288 (65.5%) and third waves 290 (78%) than in the first wave 522 (59.7%). Running nose was most prevalent in the first wave, 143 (16.4%), and least prevalent in the second wave, 16 (4.6%). Respiratory distress was the most prevalent in the third wave, 251 (67.1%), and the least prevalent in the first wave, 403 (46.1%). Sore throat occurred

more prevalent in the first wave 198 (22.7%) than in the other waves. Diarrhea 60 (16.1) and

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

vomiting 59 (15.9%) were the most prevalent in the third wave. Anosmia was more prevalent in the third wave 116 (31.2%) than in other waves and less frequently in the second wave 27 (7.8%) than in other waves. However, headache was more prevalent in the third 82 (22.5%) and first wave 145 (16.6%) than in the second wave. Body aches occurred more commonly in the second 87 (25%) and third 92 (24.6%) waves than in the first wave. (Table 1) Patients that presented in a critical condition 23 (6.2%) and severe disease 152 (40.8%) were more prevalent in the third wave than in other waves. In the second wave, most cases were mild 216 (61.9%). During the hospital stay, the severity of the patient's severity changed, and in the third wave, 72 (19.3%) critical and 145 (38.8%) severe diseases emerged. Mild-to-moderate illness was more common in the first and second waves than in the third wave. Diabetes was more common among admitted patients in the second 136 (38.8%) and third waves 179 (48.1%) than in the first wave. Hypertension was prevalent in the second 142 (40.6%) and third wave 208 (55.9%). Asthma 27 (16%), ischemic heart disease 63 (16.9%), and renal disease 47 (12.6%) were the most prevalent in the third wave (Table 1). **Symptoms Cluster in COVID-19** We found three clusters of symptoms among the admitted COVID patients: 1. Fever, cough, and respiratory distress. 2. Anosmia, headache, and anorexia 3. Sore throat and running nose. The symptom clusters differed for the three waves. In the first wave, we found three clusters; 1. Respiratory distress and cough. 2. Anosmia and anorexia. 3. Running nose and sore throat. In the second wave, we found a cluster of headaches, running nose, sore throat, and hoarseness of voice. In the third wave, we found three clusters: 1. anorexia and anosmia, 2. fever and cough, and 3. headache, diarrhea, and vomiting. (Figure 1)

#### Figure 1: Symptoms clusters in COVID-19.

313

314

315

#### Table 2: Investigation profile of the admitted patients in the three waves

Variable	Total	First wave	Second wave	Third wave	P value
	patient	Median (IQR)	Median (IQR)	Median (IQR)	
	(N)				
WBC	607	8.50	18.65	5.95	<0.001
		(6.2-11.72)	(14.55-24.00)	(1.28-10.23)	
Neutrophil	595	71.70	83.00	78.00	<0.001
(%)		(60.92-83.00)	(79.0-87.0)	(68.0-86.0)	
Lymphocyte	595	21.75	12.00	18.00	<0.001
(%)		(12.88-30.68)	(10.70-16.0)	(10.0-27.0)	
Platelet count	575	247.00	126.00	135.00	<0.001
		(189.5-324.0)	(29.9-276.00)	(31.00-250.00)	
CRP	438	12.00	18.00	39.00	<0.001
		(6.0-34.77)	(8.68-68.50)	(13.0-85.0)	
creatinine	547	0.96	1.180	1.14	<0.001
		(0.80-1.12)	(0.95-6.62)	(0.90-1.40)	
D-dimer	458	0.47	1.52	0.79	<0.001
		(0.27-1.05)	(0.62-3.56)	(0.40-1.80)	
Ferritin	369	297.00	1468.00	441.00	0.002
		(122.0-642.0)	(973.5-2050.0)	(235.5-1000.0)	

Serum	191	-	138.00	135.00	0.121
sodium			(135.0-140.8)	(132.0-138.0)	

The white blood cell count was high in the second wave, 18.65(14.5–24), and low in the third wave. The platelet count was low in the third wave 78 (68–86). CRP was much higher in the third wave 39 (13–85) and D-dimer 1.52 (0.63–3.56), and ferritin was high in the second wave 1468 (973–2050). (Table 2)

Table 3: Outcome of the admitted patient in three waves

Variable	Categories	Total	First	Second	Third wave	P
		patient	wave (N)	wave (N)	(N)	value
		(N)	%	%	%	
	Critical	107	32	3	72	
			29.9%	2.8%	67.3%	
Ultimate	Mild	627	365	183	79	
severity			58.2%	29.2%	12.6%	<0.001
	Moderate	589	383	128	78	
			65.0%	21.7%	13.2%	
	Severe	271	94	32	145	
			34.7%	11.8%	53.5%	
Duration of			13.0	12.0	7.0	
hospital stay			(8.0-	(8.0-12.0)	(4.0-11.0)	<0.001

		20.0)			
Interval		5.0	5.0	5.0	<0.001
symptom		(4.0-6.0)	(5.0-6.0)	(4.0-6.0)	
onset and					
admission					

The patient developed a more severe disease in the third wave, and the duration of hospital stay was longer in the first wave 12 (8–20). (Table 3)

# Table 4: Trend of outpatient, inpatient and virology department consultation in three waves

Trait	Total	First wave	Second wave	Third wave	P value
		Outpatient de	epartment		
Total Attended	38578	19890 (51.6)	7347 (19.0)	11341 (29.4)	
Positive	5584	3134 (15.7%)	896 (12.1%)	1554	< 0.001
				(13.7%)	
Admitted	25721	13650	5419 (73.7%)	6652	< 0.001
		(68.6%)		(58.6%)	
Death	329	127 (0.6%)	105 (1.4%)	97 (0.8%)	
Admission rate	81.3	80.6	84.4	80.1	
(%)					
Gender					

Male					
Total Attended	22595	12274 (54.3)	4341 (19.2)	5980 (26.5)	
Positive	3201	1895 (15.4%)	518 (11.9%)	788 (13.1%)	< 0.001
Admitted	15133	8541 (69.5%)	3218 (74.1%)	3374	< 0.001
				(56.4%)	
Death	208	86 (0.7%)	64 (1.4%)	58 (0.9)	
Admission rate	81.6	81.2	84.7	80.0	
(%)					
Female					
Total Attended	15981	7614 (47.6)	3006 (18.8)	5361 (33.5)	
Positive	2383	1239 (16.2%)	378 (12.5%)	766 (14.2)	<0.001
Admitted	10586	5107 (67%)	2201 (73.2%)	3278	< 0.001
				(61.1%)	
Death	121	41 (0.5%)	41 (1.3%)	39 (0.6%)	
Admission rate	80.9	80.0	84.0	80.3	
(%)					
Age group					
<40 years					
Total Attended	14264	7297 (51.2)	2354 (16.5)	4613 (32.3)	
Positive	1623	1021 (13.9)	221 (9.3)	381 (8.2)	< 0.001
Admitted	6266	3547 (48.6)	1162 (49.3)	1557 (33.7)	< 0.001
Death	49	20 (0.2)	13 (0.5)	16 (0.3)	
Admission rate	79.0	77.3	83.2	79.7	

(%)					
40-60 years					
Total Attended	12759	6920 (54.2)	2457 (19.3)	3382 (26.5)	
Positive	2097	1177 (17)	356 (14.4)	564 (16.6)	< 0.001
Admitted	9314	5099 (73.6)	1948 (79.2)	2267 (67)	< 0.001
Death	121	42 (0.6)	45 (1.8)	34 (1)	
Admission rate	80.8	80.7	82.9	79.1	
(%)					
60+ years					
Total Attended	11490	5645 (49.1)	2516 (21.9)	3329 (29.0)	
Positive	1852	929 (16.4)	316 (12.5)	607 (18.2)	< 0.001
Admitted	10101	4979 (88.2)	2300 (91.4)	2822 (84.7)	< 0.001
Death	153	64 (1.1)	47 (1.8)	42 (1.2)	
Admission rate	83.4	83.4	86.4	81.3	
(%)					
		Inpatient cor	sultation		
Trait	Total	First wave	Second wave	Third wave	P value
		N (%)	N (%)	N (%)	
Total	24501	12797 (52.2)	5317 (21.7)	6387 (26.1)	0.0004
admission					
Oxygen	14198	6865 (48.4)	3332 (23.4)	4001 (28.2)	< 0.0001
support					
Percentage of		61.8%	69.43%	75.29%	<0.0001

the patient					
getting oxygen					
ICU admission	4030	3442 (26.8%)	588 (11%)		<0.0001
Death	5057	2584 (20%)	1019 (19%)	1454	< 0.0001
				(22.7%)	
		Virology de	partment		<u> </u>
Trait	Total	First wave	Second wave	Third wave	P value
		N (%)	N (%)	N (%)	
Total					
population					
Total test	57857	26708 (46.1)	13214 (22.8)	17935 (31.0)	
Positive	12870	5962 (46.3)	2814 (21.9)	4094 (31.8)	< 0.001
Positivity rate	22.2%	22.3	21.3	22.8	
(%)					
Gender					
Male					
Total test	32517	15146 (46.6)	7591 (23.3)	9780 (30.1)	
Positive	7082	3416 (48.2)	1553 (21.9)	2113 (29.8)	< 0.001
Positivity rate	21.8	22.6	20.5	21.6	
(%)					
Female					
Total test	25312	11542 (45.6)	5619 (22.2)	8151 (32.2)	
Positive	5782	2542 (44.0)	1260 (21.8)	1980 (34.2)	< 0.001

Positivity rate	22.8	22.0	22.4	24.3	
(0/)					
(%)					
Age group					
<40					
Total test	27055	13408 (49.6)	5291 (19.6)	8356 (30.9)	
Positive	5555	2721 (49.0)	1063 (19.1)	1771 (31.9)	< 0.001
Positivity rate	20.5	20.3	20.1	21.2	
(%)					
40-60					
Total test	13033	6215 (47.7)	2570 (19.7)	4248 (32.6)	
Positive	3148	1538 (48.9)	582 (18.5)	1028 (32.7)	< 0.001
Positivity rate	24.2	24.7	22.6	24.2	
(%)					
>60					
Total test	8210	3477 (42.4)	1678 (20.4)	3055 (37.2)	
Positive	2114	911 (43.1)	369 (17.5)	834 (39.5)	< 0.001
Positivity rate	25.7	26.2	22.0	27.3	
(%)					

Confirmed COVID-19 cases were higher (15.7%) in the second wave than in the other waves, the admission rate 73.7%, and the death rate 1.4% were higher in the second wave than in other waves. The proportion of confirmed COVID-19 cases was higher among women in all waves. In the third wave, the admission rate among women 61.1% was higher than among men. The

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

number of positive cases was higher in those below 40 years in the first wave 13.9% and above 60 years in the third wave 18.2%. The admission rate of patients below 40 years was lower in the third wave 33.7%. In the second wave, the admission rate among the 40–60-year age group 79% and above 60 years age group 91.4% was higher than in other waves. In the second wave, the death rate was higher among men 1.4% and women, 1.3% In the second wave, the death rate was high in the 40–60-year age group and above 60-year age group. The admission rate was higher in patients aged above 60 years in all three waves. 52% of patient were admitted in the first wave and 75% received more oxygen in the third wave. Death was more common 51% in the first wave. The patient was tested more frequently in the first and third waves than in the second wave. The positivity was high in the third wave 22.8%. In the third wave, the positivity rate was high among women 24.3%. The incidence rate of patients above 60 years was high in the first and third waves 27.3%. (Table 4) The daily COVID-19 infection rate was higher in the third wave and the duration of the second wave was short. The first wave lasted longer than the other wave, with an elevated and gradual infection rate decline. The rate of testing was equal for all three waves. The positivity rate was higher during the third than in the first and second waves (Figure 2, Supplement 2).

## Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three waves

#### Table 5: post COVID -19 complications of the three waves

Trait	Total patient	First wave	Second wave	Third wave	P value

	600	200	200	200		
Age, Mean	45.2(15.8)	45.5(16.3)	43.6(14.3)	46.5(16.5)	0.19	
(SD)						
Sex, Male n	337(56.2)	123(61.5)	97(48.5)	117(58.5)	0.08	
(%)						
Post COVID-19	9 conditions					
Number of post	t-covid conditio	ons			0.24	
None	40(6.7)	17(8.5)	12(6)	11(5.5)		
Single	93(15.5)	38(19)	30(15.1)	25(12.5)		
Multiple	466(77.7)	145(72.5)	157(78.9)	164(82)		
Symptoms						
Feverish	16(2.7)	6(3)	4(2)	6(3)	0.7	
feeling						
Fatigue	421(70.2)	126(63)	144(72)	151(75.5)	0.03	
Cough	127(21.2)	35(17.6)	58(29)	34(17)	0.004	
Respiratory	40(6.7)	14(7)	15(7.5)	11(5.5)	0.7	
distress						
Hoarseness of	16(2.7)	9(4.5)	2(1)	5(2.5)	0.09	
voice						
Chest pain	142(23.7)	44(22.1)	40(20.1)	58(29)	0.09	
Anorexia	135(22.5)	40(20)	39(19.5)	56(28)	0.07	
Anosmia	16(2.7)	7(3.5)	4(2)	5(2.5)	0.6	
Headache	146(24.3)	46(23)	49(24.5)	51(25.5)	0.08	

Memory	152(25.4)	46(23)	64(32)	42(21.1)	0.03
disturbance					
Insomnia	73(12.2)	20(10)	29(14.5)	24(11)	0.38
Hypersomnia	4(0.7)	2(1)	2(1)		0.36
Sleep pattern	6(1)	2(1)	2(1)	2(1)	<0.99
alteration					
Arthralgia	69(11.5)	25(12.6)	28(14)	16(8)	0.15
Confusion	29(4.8)	5(2.5)	12(6)	12(6)	0.18
New onset	15(2.5)	2(1)	7(3.5)	6(3)	0.23
hypertension					
New onset	23(3.8)	8(4)	10(5)	5(2.5)	0.42
Diabetes					
Fatigue score,	4.7(2.9)	3.1(2.9)	4.2(3.3)	3.9(3.1)	0.001
mean (SD)					
Functional	90.3(7.4)	90.9(7.7)	90(7.6)	90(6.9)	0.35
status, mean					
(SD)					
Depression	143(25.2)	58(40.6)	49(34.3)	36(25.2)	0.03

The percentage of patients that developed post-COVID complications was equal in all three waves. However, patients in the second wave developed more post-covid cough and memory disturbance depression, and patients in the third wave developed more fatigue than those in other waves. However, patients in the second wave had increased fatigue scores. The functional status

of the patients was similar in the three waves. We found five symptom clusters. However, they did not differ among the three waves (Figure 3).

#### Figure 3: Symptom cluster in post COVID-state

#### **Discussion**

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

This study compared the first, second, and third COVID-19 waves in terms of presentation, outcomes, and hospital epidemiological trends. The first wave lasted longer, and however, the second wave lasted for a short period. We found age and sex differences in the admission rates in the three waves. Cough, runny nose, respiratory distress, diarrhea, vomiting, and anosmia were the most common symptom in the three waves. The symptom cluster differed among the three waves. Disease severity, duration of hospital stay, and severity markers differed. We found disparities in the frequencies of the positivity test and death rates. The three waves had similar Post COVID complications. This study was conducted at the tertiary center of Dhaka. The treatment facility differs from center to center and region to region; therefore, we cannot generalize the findings across the nation and globally. During replication, a mutation in the genetic code of SARS-CoV-2 leads to the development of a new variant. The behaviors of variants, such as virulence and transmissibility, differ [28]. WHO named the variant to be monitored with the Greek alphabet and named from alpha to zeta [29]. In Bangladesh, until September 2021, alpha, beta, and delta variants were dominant at different times creating, three waves of COVID-19: the first wave was caused by alpha, the second wave

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

was caused by beta, and the third wave caused by delta variants [18]. Epidemiological and disease characteristics differ in various studies [16,30,31]. In Bangladesh, the first wave lasted approximately 8 months, the second wave approximately 2 months, and the third wave approximately 3 months. This was due to the variations' transmissibility; delta was 63–167% more transmissible than alpha [32]. Therefore, the most susceptible people became infected faster, replacing existing variants. Delta and beta variants spread quickly in Bangladesh, and delta quickly became the dominant variant. Omicron was 2.8 times more transmissible than Delta, thus replacing Delta in a short period [33]. In this study, we found a variation in the demographic patterns across the three variants. Young people were more affected in the initial wave, as evidenced by the high number of positive cases in the virology laboratory among the young. However, the elderly had a higher positivity rate. The proportion of older adult patients in the hospitalized patients was higher in the first and third waves than in the second wave. The admission rate among the attended patients in the outpatient department was higher in the second wave than in the first and third waves. Because of their increased mobility the younger age group became infected in large numbers. Immune senescence and various comorbidities could explain the older adults' admission. The viral receptors ACE2 and CD26 are more expressed in senescent cells, which explains why older adults are more susceptible to infection [35]. The virus affinity for the receptor varies among the variants. This explains the age group variations among variants [36]. The overall number of admitted men was higher than women. However, the number of women admitted was higher in the second wave. Admission and death rates were higher among men. However, women had a higher positivity rate than men, especially in the second and third

waves. Men had higher rate of incidence of COVID-19 due to the altered immunologic response, associated comorbidity, hormonal differences, and smoking habits [35]. angiotensin-converting enzyme (ACE) receptor expression is higher in women because its genetic loci are on the X chromosome [37]. The TMPRSS2 gene is located on chromosome 21q22.3[38]. Some variants have a higher affinity for TMPRSS than for ACE II. This might explain the gender differences in the expression of the various COVID-19 variants. Again, increased testosterone levels may increase the probability of microthrombi formation [39], which is the underlying pathophysiology of severe COVID-19. The duration of Hospital admission was longer in the first wave, which was most likely due to the severity of the disease at the time of discharge. In the first wave, most patients were admitted because of isolation, and their release was determined by the time of PCR negativity. ICU admission was higher in the first wave due fear an unnecessary patient transfer to the ICU. The death rate was higher in the third wave than in other waves. The different affinities of the viruses can explain the heterogeneous presentation and clustering of various variants to the receptor. The virus's ability to escape immunity [40] can explain the mutant strain's varied presentation and severity. The three waves had slightly different post-COVID-19 complications. Further studies on its pathogenesis and immunological response are needed. Because this was a single-center study, genotyping was either not performed or was impractical for all patients. This was a retrograde study and a review of the documents. Therefore, missing

#### Conclusion

information was likely.

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

This study revealed that during the COVID-19 waves, the presenting features, outcomes, and epidemiologic trends were different. Recommendation In each of the three waves, COVID-19 occurred differently. A mutant strain of the SARS-CoV-2 was most likely the cause of these differences. Therefore, we recommend the following. 1. There should be genetic surveillance for the identification of the specific variant of interest. 2. At the onset of each wave, intensive epidemiologic surveillance should be conducted. 3. There should be diversity in each wave's strategy for disease control planning, treatment, and hospital management. Acknowledgments We are grateful to Dhaka Medical College Hospital authority for giving us permission to access the hospital records; without their help it will be impossible to conduct this study. **References:** 1. World Health Organization. GCM teleconference – Note for the Records. 10 January 2020. Subject: Pneumonia in Wuhan, China. Available from: https://www.who.int/ blueprint / 10-01-2020-nfr-gcm.pdf?ua=.

- 2. World Health Organization. Novel coronavirus (2019-nCoV). Situation Report 1. 21
- January 2020. Available from: https://www.who.int/docs/default-source /coronaviruse
- 449 /situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10 4.
- 3. WHO Director-General's opening remarks at the media briefing on COVID-19 11
- 451 March 2020, available from: <a href="https://www.who.int/dg/speeches/detail/who-director-">https://www.who.int/dg/speeches/detail/who-director-</a>
- 452 general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
- 4. https://www.worldometers.info/coronavirus/, Accessed 25 November 2021.
- 5. <a href="https://www.who.int/influenza/resources/documents/pandemic\_phase\_descriptions\_and">https://www.who.int/influenza/resources/documents/pandemic\_phase\_descriptions\_and</a>
- 455 <u>actions.pdf.</u> Accessed 25 November 2021.
- 6. https://www.history.com/news/pandemics-end-plague-cholera-black-death-smallpox.
- 457 Accessed 25 November 2021
- 458 7. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the
- transmission dynamics of SARS-CoV-2 through the postpandemic period.
- 460 Science 22 May 2020:Vol. 368, Issue 6493, pp. 860-868. DOI: 10.1126/science.abb5793
- 8. https://www.theguardian.com/world/2021/mar/22/lockdowns-return-extended-third-
- 462 <u>wave-covid-europe.</u> Accessed 25 November 2021.
- 9. https://time.com/5951490/covid-fourth-wave/ Accessed 25 November 2021.
- 10. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/. Accessed 25
- 465 November 2021.
- 11. https://www.nature.com/articles/d41586-020-02544-6. Accessed 25 November 2021.
- 12. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/. Accessed 25
- 468 November 2021.

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

13. European Centre for Disease Prevention and Control 20 Dec 2020 Threat Assessment Brief. Accessed 25 November 2021. 14. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-briefemerging-variants.html. Accessed 19 November 2021. 15. https://www.who.int/docs/default-source/coronaviruse/situation reports/20210427 weekly epi update 37.pdf?sfvrsn=a1ab459c 5&download=true. Accessed 19 November 2021. 16. Ranjan, R., Sharma, A., Verma, M.K., 2021. Characterization of the Second Wave of COVID-19 in India. medRxiv 2021.04.17.21255665. doi: 10.1101/2021.04.17.21255665 17. https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-deaths-drop-41-lowest-39-days-242425. Accessed 19 November 2021. 18. https://www.icddrb.org/news-and-events/icddrb-in-the-news. Accessed 19 November 2021. 19. WHO guidance on management of severe acute respiratory infection (SARI) when COVID19 is suspected. Accessed November 1, 2020. //www.who.int/publicationsdetail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. 20. National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID-19). 27 May, 2020. Accessed November 1, 2020.https://dghs.gov.bd/images/docs/Guideline/ COVID. Guideline. pdf. 21. Bari R and Sultana F (2021) Second Wave of COVID-19 in Bangladesh: An Integrated and Coordinated Set of Actions Is Crucial to Tackle Current Upsurge of Cases and Deaths. Front. Public Health 9:699918. doi: 10.3389/fpubh.2021.699918

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

22. Devnath P, Hossain MJ, Emran TB, Mitra S. Massive third wave of COVID-19 outbreak in Bangladesh: a co-epidemic of dengue might worsen the situation. Future Virol. 2022 Jan:10.2217/fvl-2021-0182. doi: 10.2217/fvl-2021-0182. Epub 2022 Mar 8. PMID: 35284001; PMCID: PMC8906578. 23. Post-COVID conditions. Centers for disease control and prevention, USA. Accessed 19 July 2021. From https://www.cdc.gov/coronavirus/2019-ncov/long-termeffects/index.html 24. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Board on the Health of Select Populations; Institute of Medicine. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Washington (DC): National Academies Press (US); 2015 Feb 10. Available from: https://www.ncbi.nlm.nih.gov/books/NBK274235/ DOI: 10.17226/19012. 25. Chalder, T.; Berelowitz, G.; Pawlikowska, T.; Watts, L.; Wessely, S.; Wright, D.; Ε. Р. Wallace, (1993). "Development of a fatigue scale". Journal of Psychosomatic Research. 37 (2): 147–153. ISSN 0022-3999. PMID 8463991 26. Karnofsky D. Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191–205. 27. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: validity of a brief depression severity measure. Journal of general internal medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.x

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

28. Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. Clin Pathol. 2022 Feb 3:15:2632010X221075584. doi: 10.1177/2632010X221075584. PMID: 35141522; PMCID: PMC8819824. 29. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications. Accessed on 01.11.21 30. S. Iftimie, A. F. López-Azcona, I. Vallverdú et al., "First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus. Spain," PLoS One, vol. 16, no. 3, Article ID e0248029, 2021. 31. Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasiyaj B, Kuratong S, Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand. Adv Prev Med. 2021 Oct 8; 2021:5807056. doi: 10.1155/2021/5807056. PMID: 34659835; PMCID: PMC8519693. 32. Earnest, R, Uddin, R, Matluk, N, et al. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha New England, USA. Cell in Rep Med. 2022;3(4):100583. https://doi.org/10.1016/j.xcrm.2022.100583 33. De La Cruz-Hernández, S., & Álvarez-Contreras, A. (2022). Omicron Variant in Mexico: The Fourth COVID-19 Wave. Disaster Medicine and Public Health Preparedness, 1-2. doi:10.1017/dmp.2022.160 34. Monod M, Blenkinsop A, Xi X, Hebert D, Bershan S, Tietze S, Baguelin M, Bradley VC, Chen Y, Coupland H, Filippi S, Ish-Horowicz J, McManus M, Mellan T, Gandy A, Hutchinson M, Unwin HJT, van Elsland SL, Vollmer MAC, Weber S, Zhu H, Bezancon A, Ferguson NM, Mishra S, Flaxman S, Bhatt S, Ratmann O; Imperial College COVID-

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

19 Response Team. Age groups that sustain resurging COVID-19 epidemics in the United States. Science. 2021 Mar 26;371(6536):eabe8372. doi: 10.1126/science. abe8372. Epub 2021 Feb 2. PMID: 33531384; PMCID: PMC8101272. 35. Al-Bari MAA, Hossain S, Zahan MK. Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population. World J Radiol. 2021 Jan 28;13(1):1-18. doi: 10.4329/wjr. v13.i1.1. PMID: 33574990; PMCID: PMC7852349. 36. Han Y, Wang Z, Wei Z, Schapiro I, Li J. Binding affinity and mechanisms of SARS-Biotechnol 2021; CoV-2 variants. Comput Struct J. 19:4184-4191. 10.1016/j.csbj.2021.07.026. Epub 2021 Jul 26. PMID: 34336146; PMCID: PMC8312055. 37. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics. 2019; 13:2. 38. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020; 10:779– 782. 39. Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A, Lutsey PL. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med. 2020; 180:190–197. 40. Liu H, Wei P, Kappler JW, Marrack P, Zhang G. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. Front Immunol. 2022 Jan 27; 13:825256. doi: 10.3389/fimmu.2022.825256. PMID: 35154144; PMCID: PMC8828474.

### **Supporting Information:**

- 1. Supplement 1: Patient selection and distribution of the patient for this cross-sectional study
- 2. Supplement 2: Difference in daily oxygen support, daily positive cases and daily test variability in three waves




Figure 1


#### Figure 1: Symptoms clusters in COVID-19

a. According to general clusters of symptoms, We found three clusters of symptoms among the admitted patients with COVID-19: 1. Fever, cough, and respiratory distress. 2. Anosmia, headache, and anorexia, 3. Sore throat and running nose. b. In the first wave, we found three clusters 1. Respiratory distress and cough, 2. Anosmia anorexia, and 3. Running nose and sore throat. c. In the second wave, we found a cluster headache, running nose, sore throat, and hoarseness of voice. d. In the third wave, we found three clusters 1.


Anorexia and anosmia 2 Fever and cough and 3 headache, diarrhea, and vomiting medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

We did the network analysis with tidy verse and q graph using R (v4.1.1).


(cov-COVID-19, Fvr-Fever, Cgh-cough, Rnn-Running nose, Rsd-Respiratory distress, Srt-Sore throat, Hrv-Hoarseness of voice, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, Lth-Lethargy, Ach-Body ache)



medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.



b



С

# Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three surges

- a. Test positivity-The first surge remained longer and the second surge was narrowest. The daily number of positive cases was high in the second and third surge.
- Daily admission-Number of daily admissions was highest in the initial part of the first wave and third wave
- Daily death-Number of daily deaths was highest in the initial part of the first wave and third wave
  - (The first, second, and third waves extend from April 2020 to January 2020, February 2021 to May 2021, and June 2021 to September 2021, respectively)

medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.




Figure 3

### Figure 3: Symptom cluster in post COVID-state

There were five cluster of symptoms in the post-COVID state, 1-diarrhea and vomiting, 2-fatigue and anorexia, 3-memory loss and insomnia, 4-persistent cough and sputum, 5-sore throat and respiratory distress.

We did the network analysis with tidy verse and q graph using R (v4.1.1). (cov-COVID-19, Ftg-Fatigue, Ptc- persistent cough, Spt-sputum, Rsd-Respiratory distress, Srt-Sore throat, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, NHT: new onset hypertension, NDM: new onset diabetes, Mmd-Memory disturbance

medRxiv preprint doi: https://doi.org/10.1101/2022.12.14.22283379; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.